2023 was a record-breaking year for FDA approvals for Pfizer, with nine new molecular entity approvals and many more approvals for new indications in already approved products, marking a very productive year of pipeline execution for Pfizer. Our research and development (R&D) success rates are ...
“As we look forward, we are confident in our future. With our clear strategic roadmap, a robust pipeline of potential innovative medicines and vaccines and a talented team laser-focused on execution, we believe we are on course to deliver significant shareholder value.” Pfizeri...
Product Pipeline Research Sites Products How Drugs are Made Branded vs. Generic Biologics & Biosimilars Commitment to Quality Global Supply Manufacturing Sites Medicine Safety Health Literacy Treatment Choices Partnering With Patients Tips for Patients Reporting Adverse Events Counterfeiting Product Safety Produc...
“We are entering 2024 with a solid foundation. We believe our commitment to execution, maximizing the performance of our new products, and delivering the next wave of pipeline innovation will fuel Pfizer’s growth and make a difference in the lives of patients everywhere.” D...
with a diverse pipeline of innovative vaccine and anti-infective treatment candidates," said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer. "With our unique scientific capa...
Research and Pipeline Social Responsibility Vaccines October 2024 10.22.2024 Corporate Partnerships Pfizer Supplies One Billionth Pneumococcal Conjugated Vaccine Dose for Vaccination of Children in Lower- Income Countries Through Gavi, the Vaccine Alliance ...
Tuesday’s deal with Flagship is the latest development in Pfizer’s ongoing quest to deepen its pipeline. In March 2023, the pharma powerhouse dropped $43 billion to acquire cancer-focused Seagen, gaining access to its library of antibody-drug conjugates. This deal came less than a year af...
But Pfizer is pinning its hopes on mergers and acquisition and a record pipeline to help the company navigate its post-pandemic boom. That pipeline includes Pfizer'sRSV vaccinefor use in older adults, which could win FDA approval later this month. It also includes the company's new pneumococca...
Yes, great. Thanks for taking my questions. So maybe a couple if I could on the pipeline. So Prevnar 25-valent you mentioned starting Phase 3 in adults this year. Just curious if you can comment on what you've seen so far gives you comfort in moving up for when we might see the ...
2023, we expect to once again set records, with potentially the largest number of new product and indication launches that we’ve ever had in such a short period of time. We believe that the combination of these expected near-term launches, additional pipeline product...